Abionyx Pharma SA

Abionyx Pharma SA pioneers biotech therapies for renal, eye, and cardiovascular diseases, with a robust pipeline including CER‑001, CER‑002, and CER‑209.

Abionyx Pharma SA is pioneering novel therapies for renal and eye diseases, with flagship candidates CER‑001, CER‑002, and CER‑209 targeting heart, metabolic, and liver disorders.